Work

HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families

Year: 2015

Type: article

Abstract: We and others recently discovered HHLA2 as a new B7 family member and transmembrane and immunoglobulin domain containing 2 (TMIGD2) as one of its receptors. Based on a new study we propose that HHLA2 may represent a novel immunosuppressive mechanism within the tumor microenvironment and hence could be a target for cancer therapy. TMIGD2 may be another therapeutic target.

Source: OncoImmunology

DOI: 10.1080/2162402x.2015.1026534

Authors: Murali Janakiram, Jordan M Chinai, Aimin Zhao, Joseph A Sparano, Xingxing Zang

Institutions: Albert Einstein College of Medicine, Montefiore Medical Center, Shanghai Jiao Tong University, Renji Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,913